GT Biopharma Receives Institutional Review Board Approval to Proceed With in Human FDA Phase 1 Clinical Trial April 8, 2019
GT Biopharma Announces Closing of Private Placement Financing and Provides Business Update February 6, 2019
GT Biopharma Presents Positive Preclinical Data of Tri-specific NK Cell Engager (TriKE) at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition December 6, 2018
GT Biopharma Announces Presentation of Two Abstracts at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition November 20, 2018
GT Biopharma Reports Third Quarter 2018 Financial Results and Provides Business Update November 15, 2018
GT Biopharma Receives FDA Clearance to Commence First-in-Human Phase 1 Study of its First-in-Class Tri-Specific Killer Engager (TriKE), GTB-3550, for the Treatment of Acute Myelogenous Leukemia, Myelodysplatic Syndrome and Mastocytosis November 1, 2018
GT Biopharma's Chairman and Chief Executive Officer, Raymond W Urbanski MD, PhD, Provides Further Insight into the Recent Activity in the Natural Killer Cell (NK) Space October 4, 2018
GT Biopharma Announces Postive Results For Two Next Generation Trikes In Solid Tumors September 13, 2018
